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Abstract 
The use of Individual Patient Data (IPD) in Network Meta Analysis (NMA) is becoming 
increasingly popular. However, as most studies do not report IPD, most NMAs are carried out 
using aggregate data (AD) for at least some, if not all, of the studies. We investigate the 
benefits of including varying proportions of IPD studies in an NMA.  
Several models have previously been developed for including both AD and IPD in the same 
NMA. We carried out a simulation study based on these models to examine the impact of 
additional IPD studies on the accuracy and precision of the estimates of both the treatment 
effect and the covariate effect. We also compared the Deviance Information Criterion (DIC) 
between models to assess model fit. An increased proportion of IPD resulted in more accurate 
and precise estimates for most models and datasets. However, the coverage probability 
sometimes decreased when the model was misspecified. The use of IPD leads to greater 
differences in DIC, which allows us choose the correct model more often.  
We analysed a Hepatitis C network consisting of three IPD observational studies. The ranking 
of treatments remained the same for all models and datasets. We observed similar results to the 
simulation study: the use of IPD leads to differences in DIC and more precise estimates for the 
covariate effect. However, IPD sometimes increased the posterior SD of the treatment effect 
estimate, which may indicate between study heterogeneity. We recommend that IPD should be 
used where possible, especially for assessing model fit.  
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Glossary 




Explanation   
     Number of events in the  
   arm of the     trial. In 
the case of Hepatitis C infection this is the number of 
patients who achieved Sustained Virological 
Response (SVR)   
      Binary outcome for the  
   patient in the     arm of 
the     trial. In the case of Hepatitis C infection it is 
whether or not a patient attained SVR   
     Probability of an event in the  
   arm of the     
trial.   
      Probability of an event for the individual patient l in 
the     arm of the     trial.   
     Proportion of patients with the binary covariate, or 
mean of the continuous covariate, in the     arm of 
the     trial.   
      Value for the covariate for patient l in the  
   arm of 
the     trial.   
   Effect of the covariate   
    Effect of the covariate interacting with treatment k 
when interactions are considered independent or 
exchangeable   
      Effect of the covariate interacting with the treatment 
in the     arm of the     trial when interactions are 
considered independent or exchangeable   
    Mean of covariate effect across treatments when 
interactions are considered exchangeable   
    Standard deviation of covariate effect across 
treatments when interactions are considered 
exchangeable   
    Baseline risk in study i   
     Study specific treatment effect in the  
   arm of the 
    trial   
    Standard deviation of study specific treatment effects  
    True effect of treatment k relative to the reference 
treatment   
      True effect of the treatment in the  
   arm of the     
trial relative to the reference treatment   
S  Number of simulations   
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1. Introduction 
Network Meta Analysis (NMA) is a method for assessing the entire evidence base for a 
particular disease when three or more treatment options are available
1
. It is an extension of 
traditional pair-wise Meta Analysis (MA), which is used when directly evaluating two 
treatment options. NMA combines direct and indirect evidence to obtain effect estimates 
comparing all treatments against all other treatments in the network.  
While most trials publish only the summary statistics (Aggregate Data (AD)) for patients as a 
whole, some may also be able to provide Individual Patient Data (IPD). There are both benefits 
and drawback to IPD NMAs
2-8
. On the positive side IPD allows for a more in-depth and 
accurate analysis of the data, as we can explore how patient covariates influence the treatment 
effect,   , as defined in Figure 1. We can therefore account for differences in the patient 
covariates between arms. It also allows separation of within study associations of the 
covariates from across study associations. It facilitates harmonization between trials, both in 
terms of outcome and analysis, and encourages input from the clinical investigators. However, 
IPD can be quite time consuming to obtain, and only certain types of IPD may be available 
which could potentially lead to bias. For example, IPD may only be available for observational 
studies, or perhaps certain investigators may be more likely to share their data than others. 
There are also a number of data protection issues that arise from using IPD. Finally, even when 
the IPD are obtained, much more computational power is required to carry out the analysis. As 
it is unlikely that investigators will obtain a full IPD network, the best way to make use out of 
the data is to be able to combine both IPD andAD in the same NMA. Therefore, a number of 
models have been developed for this purpose
9-11
.  





 found that there are differences in results between IPD and AD, and encourage 
researchers to consider this approach. However, there remains a question as to whether the 
marginal benefit is worth the additional time involved. Tudur Smith et al
13
 also found IPD MAs 
to be beneficial, but note that "in many cases, similar results and conclusions can be drawn 
from IPD-MA and AD-MA. Therefore, before embarking on a resource intensive IPD-MA, an 
AD-MA should initially be explored and researchers should carefully consider the potential 
added benefits of IPD."  
Therefore, this paper aims to quantify the impact of including IPD studies in NMA. A 
simulation study is carried out to examine the impact of additional IPD studies on:  
1. The accuracy of the point estimate of both the treatment effect and the covariate 
effect.  
2. The posterior Standard Deviation (SD) from the model’s estimate of both the 
treatment effect and the covariate effect.  
3. The coverage probability, which is the proportion of the time that the Credible 
Interval (CrI) contains the true effect.  
4. The Deviance Information Criterion (DIC)14, which assesses model fit.  
We compare the results of this simulation study for both Randomised Controlled Trials (RCTs) 
and observational studies. We also analyse a Hepatitis C network consisting of three IPD 
observational studies to ascertain how different amounts or combinations of IPD studies affect 
results.  
A simulation study has previously been undertaken by Jansen
5
. He found that the use of IPD 
does increase precision and reduce bias. We extend his work by examining the coverage 
probabilities and the DIC. We also explore a number of different model assumptions for the 
interaction between covariates and treatments.  
This paper is organised as follows: Section 2 describes the model development, construction of 
the simulation study, and the Hepatitis C network. Section 3 presents the results of both the 
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simulation study and the Hepatitis C network. A general discussion and some 
recommendations are provided in Section 4.  
2. Methods 
2.1 Model Development 
We examine models relating to a binary outcome (e.g. death or cure), and a covariate which can 
either be binary or continuous. Donegan et al  [10] identify a number of different assumptions 
for interactions with the covariates. From these weexamine three models in detail; where the 
interactions are one of independent, exchangeable or identical. An identical interaction can also 
be referred to as a "prognostic variable", while independent and exchangeable interactions can 
be referred to as "effect modifiers". To illustrate the interaction modelling options we take the 
example of a binary covariate which reduces the probability of being cured. If there is an 
identical interaction with all treatments then, in this case, one’s probabilityof being cured 
decreases by a fixed amount regardless of which treatment is taken. However, another 
possibility is that certain treatments may target this covariate more effectively than others, and 
therefore possessing this covariate may be worse on one treatment than on another. In this 
scenario interactions can be considered either completely independent, or exchangeable, which 
means they are still different but come from the same underlying distribution.  
The first model assumes independent treatment by covariate interactions. The effect of 
treatment 1 (the reference treatment) is set to zero in the model with all other treatments being 




where     is the probability of an event in the  
   arm of the     trial. This probability comes 
from the effect of the     study,   , the treatment effect in the  
   arm of the     trial,    , the 
covariate effect interacting with each treatment,     , and the proportion with the covariate of 
interest for a binary covariate, or the mean of a continuous covariate in the     arm of the     
trial,    . For the IPD part, let      be the probability of an event for the  
   patient in the     
arm of the     trial and      is the covariate value for patient l in the  
   arm of the     trial. 
In the case of the IPD dataset we can also include the trial specific covariate effect   . As this 
model assumes that the interaction with the covariate is independent for each treatment, there is 
a separate prior for the covariate associated with each treatment. The covariates are centered in 
the model, as was done in Donegan et al  [10].  
The second model assumes that treatment by covariate interactions are exchangeable, i.e. that 
the interactions are different for each treatment, but that they come from a common 
distribution. With this assumption the model stays the same as above but the priors differ, as 
detailed later in this section.  
The third model assumes that treatment by covariate interactions are identical. Hence the 
models are now:  
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All three models are represented as Directed Acyclic Graphs (DAGs) in Figure 1.  
 
The prior distributions for the parameters chosen for this model are              
  , 
                  
  ,              
  ,             ,              
  . We can 
adjust for trials with arms greater than two by following Dias et al  [15]. For the independent 
model the prior on each   is              
   for each treatment by covariate interaction. 
For the exchangeable model the distribution for each   is           
  , with    
             and             . For the identical model the prior is             
    
The prior distributions for   are chosen in order to have an approximate uniform distribution 
on the log odds ratio. Kass and Wasserman  [16] point out that the properties of a prior on one 
scale can differ when transformed to another scale. A seemingly vague prior such as    
          is not vague on the inverse log odds scale, as most of the distribution is close to 
either 0 or 1. This is illustrated in Figure 2. However,        was chosen such that two SDs 
on each side of the mean covered 95  of the distribution.    represents the between trial SD 
of the treatment effect, which covers (0, 1) on the probability scale (rounded to four figures).  
2.2 Simulation Study 
A simulation study was carried out in order to assess the impact of using IPD studies. IPD was 
simulated for eight studies and this was aggregated. We then used each data point in a nine 
iteration loop to compare the results from using the AD from the eight studies with no IPD, to 
the results obtained from analysis including one more IPD study each time until we eventually 
used a full IPD network. This was repeated at least 100 times in order to reduce Monte Carlo 
error. The accuracy and precision of our model’s estimate of the treatment effect and covariate 
effect, the coverage probabilities, and difference in DIC between models were assessed as the 
number of IPD studies increased. Models were run using Markov Chain Monte Carlo (MCMC) 
simulation in the JAGS software package
17
.  
Two different interactions between treatments and covariates were examined:  
 The covariate effects are identical for each treatment and one value is simulated 
from               
 The covariate effects are exchangeable between treatments and the value for 
each treatment is simulated from               
 
This distribution was chosen for the covariate effects as it is approximately uniform in the 
transformed space as described in Section 2.1. These were examined for both RCT and 
observational studies, as well as for a binary and a continuous covariate, which came to eight 
scenarios in total. For each scenario the three modelling assumptions of independent 
interactions, exchangeable interactions and identical interactions were explored. A tree 
diagram which illustrates all scenarios and modelling options for the simulation study is shown 
in Figure A1 in the appendix.  
 
There were five treatment regimens in the network. Each study had two arms. In order 
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to keep the studies as generic as possible the treatments were randomly assigned to each study 
arm. Other values were simulated as follows:  
   was simulated from              as it was a vague distribution that is 
approximately uniform on the inverse logit scale as seen in Figure 2.  
 d was simulated from              as it was a vague distribution that is 
approximately uniform on the inverse logit scale as seen in Figure 2.  
 Number of patients generated from a rounded               for the first arm 
of each trial. This was then doubled and patients were then randomly assigned to one of 
the arms so both arms did not necessarily have the same number of patients. This 
method was chosen to more accurately reflect the reality of patients being recruited first 
and then assigned to an arm. This was applied for both the RCTs and the observational 
studies. As a consequence of this approach the number of patients in each arm of a trial 
will be similar, although the covariate make-up of the patients will differ for 
observational studies as highlighted in the next step.  
 In the case of binary covariates the probability of having the covariate was 
generated from              . The covariate for each individual patient was then 
generated from a Bernoulli distribution using the simulated probability. For RCTs one 
probability was generated per study. As a consequence the underlying distribution for 
both arms is the same. However, a known issue with observational studies is that there 
can be systematic differences between arms as they have not been randomly assigned
18
. 
In order to reflect these differences the probability of having the covariate was 
generated separately for each arm.  
 In the case of continuous covariates the mean was simulated from 
             . The covariate for each individual patient was then generated from a 
truncated normal distribution. This was done to allow the continous and binary 
scenarios to be as similar as possible in terms of the effect of the covariate, so as to 
allow comparison between the two scenarios. The covariate for each individual patient 
was bounded either below by 0 (if the mean was less than 0.5) or above by 1 (if the 
mean was greater than 0.5). The other side was bounded by the same distance from the 
mean, in order to maintain the symmetry of the distribution. For example, if the mean of 
the distribution was 0.3 then the individual patient covariates were bounded between 
(0, 0.6). The SD was set at a sixth of the range of the distribution, in order to limit the 
amount of truncated values. For RCTs we used the same mean for both arms in a study, 
however for observational studies we generated the mean separately foreach arm. As 
was the case with the binary covariates, the distribution was generated at the study level 
for the RCTs and at an arm level for observational studies.  
The probability of an event,     , in each study i and each arm j, was computed on the basis of 
the     study effect,   , the treatment effect,     , and the effect of each of the baseline 
characteristics,          , where      is a the covariate for patient l in arm j of study i.  
                               
The observed event,     , is then calculated from a                 for each patient l, in arm j 
of study i based on the above probability.  
 
The three models were tested to assess how well they predicted the true treatment 
effects and covariate effects. A burn in of 20 000 iterations was tested for convergence by 
checking if the Gelman-Rubin statistic
19
 was less than 1.1. Following this another 10 000 
iterations were sampled for our estimates. If the convergence condition was not met the number 
of iterations was doubled (both for the burn in and for the samples for estimation), and then 
tested again until the Gelman-Rubin statistic was less than 1.1. If the chains had not converged 
 This article is protected by copyright. All rights reserved. 
after a burn in of 320 000 the corresponding simulation was excluded from the analysis. For the 
full IPD dataset it can take approximately five minutes to complete 20 000 iterations with 
binary covariates, and 17 minutes to complete 20 000 iterations with continuous covariates. We 
were prepared to allow the model run 16 times longer than this to converge. Given the amount 
of simulations required we decided it was not feasible to include chains that had not converged 
by this point. This occurred for less than 1  of chains. For each set of simulated values we 
analysed all three models and all nine possibilities for the proportion of IPD studies. Therefore, 
if the chainsdid not converge for one of the models in a particular simulation the results for the 
two other models in the simulation, and all other eight possibilities for proportions of IPD 
studies were excluded from the analysis, in order to eliminate any potential bias due to 
differing simulations. The simulations took approximately 18 000 computing hours, run over 
parallel sessions. The exact number of simulations for each of the eight scenarios are detailed 
in the appendix. There are more simulations completed for the scenarios that involve binary 
covariates since each simulation for the continuous covariate required longer computation 
time.  
Coverage probability was examined to ascertain how often the estimate of the treatment effect 
was in the 95  CrI. The Mean Absolute Error (MAE) was also assessed by looking at the 
mean absolute difference between the estimates and the true values for treatments 2-5 as 
defined as follows:  
 
        
 
           
 
   
 
 




where    is our model’s estimate of the effect of treatment k and S is the total number of 
simulations. Treatment 1 was excluded as this is our reference treatment, which was set to 0. 
When identical covariate interactions were simulated the accuracy of the estimates for   were 
assessed by:  
 
        
             
 
                               
        
 
              
 
 
   
 
                                    
 (4) 
where    is our model’s estimate of the effect of the covariate under the identical interaction 
assumption, and    is our model’s estimate of the effect of the interaction of the covariate with 
treatment k under the exchangeable and independent interaction assumptions. When 
exchangeable interactions were simulated the accuracy of the estimates for   was assessed by:  
 
        
 
           
 
   
 
 




Note that for the case of the identical model each     will be the same. Precision is obtained 
from the posterior SD. The DIC was calculated and models were ranked according to which 




2.3 Applied Example in Hepatitis C Infection 
We used studies from a Hepatitis C network to test our conclusions. 36 potential studies, 
comprising of 20 RCTs and 16 observational studies, were identified by a systematic review. 
We attempted to make contact with the authors of all the studies inorder to collect as much IPD 
as possible. Our intention was to conduct a full IPD NMA. We received anonymised IPD from 
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), which highlights the 
difficulty in obtaining IPD. We limited the network used in this paper to these three 
observational studies in order to allow us compare a full AD network to a full IPD network. 
Notwithstanding the risk of "data accessibility bias" in the typeof studies for which IPD are 
available
24
, we proceed to analyse these data in order to illustrate our approach.  
Using these three studies we had a network of 10 treatment regimens in total. However, most 
treatment regimens had been considered in only one study in our IPD network so we decided to 
restrict our network to treatments that appeared in more than one study. We restricted our 
analysis to patients with a subtype of the disease known as Hepatitis C genotype 1 (and 
therefore treatment regimens which are indicated for genotype 1), who had received treatment 
for at least 12 weeks. This resulted in a network of 4 treatment regimens as listed in Table 2. 
The treatment regimens in each study, as well as the number of patients per arm are detailed in 
Table 3. Figure 4 shows the network diagram.  
3. Results 
3.1 Simulation Study 
In this section we compare the three models in terms of coverage probability, MAE of the 
estimates, and posterior SD. Ideally, we would like the coverage probability to be as close to 
the target (in this case 95 ) as possible, while minimising the MAEs of the estimates and 
posterior SDs. We also assess the effect of additional IPD on these outcomes and explore when 
the DIC can be used to choose between models. A summary of all results in this section is 
presented in Tables 9 and 10 in the discussion.  
The results obtained when using a binary covariate and a continuous covariate followed 
the same trend. However, the effect of IPD was sometimes more pronounced for binary 
covariates. For the most part, there was no noticeable difference between the results from the 
simulated RCTs and observational studies. For clarity and brevity, only the results from the 
scenario using RCTs with a binary covariate are presented in the main text. Graphs for all four 
scenarios are included in the appendix.  
3.1.1 Coverage Probability 
Figure 5 shows the coverage probability. Low coverage probability indicates that we have 
underestimated the uncertainty that is present; whereas coverage probability that is too high 
indicates that we have overestimated uncertainty. In our results we use the term "misspecified 
model" to mean that in the inference phase of our simulation the model that was fitted differed 
from the model that was used to generate the data from that same simulation.  
Note that the coverage for some misspecified models is quite far away from the target 
of 95 . When the identical model is used incorrectly the coverage of both the treatment effect 
and the covariate effect is much lower than the target. Meanwhile, for the covariate effect, the 
coverage of the independent model is much lower than the target when the true interactions are 
identical. The coverage of both of these misspecified models becomes even worse when extra 
IPD are included. A decrease in coverage probability is due to either a less accurate estimate or 
smaller posterior SD. We will see in Section 3.1.2 that MAEs of the estimates do not tend to 
increase with extra IPD, so most of the decrease in coverage is due to smaller posterior SD. 
This indicates a potential issue with IPD; it can cause over confidence when the incorrect 
model is chosen.  
When we only have AD the coverage of the covariate effect for the identical model is 
too low regardless of whether it is correct or not. However, when the interactions are in fact 
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identical the coverage increases as we include more IPD. When the majority of the studies have 
IPD then the coverage is too high. An increase in coverage probability can be caused by a more 
accurate estimate or a larger posterior SD. We will see in Section 2 that posterior SDs do not 
tend to increase with extra IPD, and most of the increase in coverage is due to smaller MAEs of 
the estimates.  
Excessively large posterior SDs can also be seen in the majority of points for the exchangeable 
model, especially for the coverage of the covariate effect when it is the correct model. Here the 
coverage is 100  in all cases, which indicates that the posterior SD should be much smaller. 
However, in this scenario the independent model is almost exactly on the 95  line.  
For the treatment effect the inclusion of IPD shows evidence of a very slight increase of 
coverage, but sometime this is further away from the target probability.  
 
3.1.2 Mean Absolute Errors and Posterior SDs 
Figure 6 shows the MAEs of the estimates and posterior SD from the JAGS output of the 
treatment effect and covariate effect vs percentage of Individual Patient Data (IPD) studies. It 
demonstrates the importance of choosing the correct model, or at the very least, making a 
distinction between an identical interaction model (prognostic variable), as defined in 
Equations 2a and 2b, or a non-identical interaction model (effect modifier), as defined in 
Equations 1a and 1b. As we may have assumed, correctly choosing between an identical or 
non-identical model gives the smallest MAEs for both the estimates of the treatment effect and 
the covariate effect. However, the identical model produces the smallest posterior SDs for the 
covariate effect regardless of which model is correct, even though it has the highest MAE for 
both the estimate of the covariate and the treatment effect when the true interactions are in fact 
exchangeable. In this situation the posterior SD is quite a bit smaller than the MAE of the 
estimate, which would explain the poor coverage of the model. Again when true interactions 
are exchangeable, the posterior SD of the identical model for the treatment effect is also 
smaller than the MAE of the estimate, and is in fact the smallest posterior SD when the 
majority of studies are AD. This discrepancy between the MAE of the estimate and posterior 
SD highlights the danger of assuming an identical model when this isn’t the case. The MAEs of 
the estimate from the non-identical models don’t differ much between the two scenarios 
simulated from models assuming identical and non-identical interaction effects, but the error of 
the estimate obtained from the model assuming identical interaction is shifted quite far up 
when it is chosen incorrectly.  
The posterior SD of the treatment/covariate effect for the exchangeable model is much higher 
than the corresponding MAE of the estimates in all cases. This is the reason why the coverage 
probability for the exchangeable model is too high. For covariate effects, the posterior SD is 
much higher for the exchangeable model than for the other two models. The exchangeable 
model incorporates all five interactions into one distribution, whereas the other models need to 
just estimate one effect (identical), or estimate five completely separate effects (independent).  
The covariate effect is generated from a              distribution. The mean of the absolute 
values from this distribution is 1.46, which is quite close to the MAE of the estimate of the 
covariate effect when the incorrect model is chosen. This implies that we gain very little 
information about the covariate when a non-identical model is chosen incorrectly.  
All models have some MAEs of the estimates and posterior SD which have been decreased by 
including extra IPD. This can particularly be seen for the treatment effects and the 
non-identical models. The effect of IPD mainly follows a slightly convex downwards slope, 
which means that most of the benefit of IPD comes from the first few studies, with the marginal 
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benefit decreasing the more IPD that is included in the NMA.  
3.1.3 Deviance Information Criterion 
As we have demonstrated the importance of choosing the correct model, we need to check how 
well this can be undertaken by comparing the DIC across models, and whether IPD can be of 
benefit here. Examining Figure 7 we can see that there is quite a large difference in our ability 
to choose between models, even when we include a small number of IPD studies, as compared 
to none. When the true interactions are identical, using the DIC we can correctly choose the 
identical model over the independent interaction model approximately 60  of the time with a 
full IPD dataset, whereas this can rarely be done with a full AD dataset. In a small number of 
instances the DIC can also choose identical over exchangeable or exchangeable over 
independent. This is what we may have expected as the exchangeable assumption is 
somewhere between identical and independent. When the true interactions are exchangeable, 
the DIC is even more powerful. While there is no difference between models with the AD 
dataset, using the DIC allows us to differentiate correctly between models up to 100  of the 
time with the full IPD dataset. Even including one IPD study has a considerable effect on the 
DIC. Again, we see the marginal benefit decreasing as more IPD are included in the NMA. 
There seems to be a clear distinction between either using the identical model or using one of 
the other two models. However, there is no difference between the exchangeable and 
independent models.  
While we see some of the same patterns with continuous covariates it is less pronounced. As 
was the case with the binary covariate, when using the full AD dataset we cannot distinguish 
between models. While there is more of a difference in DIC when IPD are included, differences 
in DIC do not occur with the same frequency as when using binary covariates (see Figure A9 in 
the appendix).  
 
To understand the reason why the DIC is more powerful for true exchangeable interactions, we 
examine the SD of the interaction of the covariate with the five treatments for the independent 
and exchangeable models, as seen in Figure 8. There is clearly a larger SD when the 
interactions are truly different. Therefore, if the model incorrectly assumes that there is a 
difference between treatments, the estimates will not be as diverse as in a truly exchangeable 
scenario, and so there is not as much of a difference between an identical and non-identical 
model in a truly identical scenario. We can also note the the SD in the exchangeable scenario 
increases with more IPD studies. So as the model gets more information about the covariates it 
can estimate them to be further apart. The true effects are simulated with an SD of 1.8318, 
which is quite close to the estimate from a full IPD dataset. Conversely, in the truly identical 
scenario, the SD slightly decreases with more IPD, i.e., it gets closer to the true SD of 0.  
3.1.4 RCT vs Observational Studies 
The main difference between RCTs and observational studies is that the observational studies 
produce a more accurate estimate of an identical covariate effect when we have mainly AD 
studies (see Figure A7). Under the identical model the observational studies provide estimates 
at different covariate levels in the two arms and thus have a smaller MAE of the estimates when 
compared to RCTs, which will measure both arms at approximately the same level of the 
covariate because of randomisation.  
We may have expected a greater difference in the accuracy of the treatment effect between the 
RCTs and the observational studies, as the RCTs are better quality trials which balance patient 
level covariates by design. While the MAEs of the estimates are slightly higher in all scenarios 
for the observational studies as compared to the RCTs, the difference is not large enough that 
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we can confidently conclude that it is not due to chance (see Figure A5).  
3.2 Applied Example in Hepatitis C Infection 
We now present the results of all eight possible datasets for the Hepatitis C network. These 
consist of a full AD dataset, a full IPD dataset, and the six mixed combinations of either one or 
two IPD studies out of the three possible IPD studies. We willalso present the results using the 
three model assumptions of independent, exchangeable and identical interactions. A tree 
diagram which illustrates all dataset combinations and modelling options is shown in Figure 
A2 in the appendix.  
3.2.1 Deviance Information Criterion 
Table 4 shows the DIC for the three models using the eight different datasets. Models with a 
smaller DIC are considered better. Examining the difference in DIC for one IPD study, we can 
see that ICORN is the only study which shows a difference between models. This is the only 
study to include all four treatments. In this case the DIC from the independent and 
exchangeable models are at least three lower than identical, which indicates a better model fit. 
Using IPD from either of the othertwo studies on their own does not allow us distinguish 
between models. In fact, we only see a difference of greater than 3 between any models when 
we include IPD from ICORN. However, when IPD from TRIO is included in addition to IPD 
from ICORN the difference in DIC decreases. In fact, the difference between identical and 
exchangeable falls below 3 in this case. This possibly demonstrates some discrepancy between 
TRIO and ICORN. Overall we conclude that one of the non-identical (effect modifier) models 
is more appropriate in this case.  
3.2.2 Credible Intervals and Posterior SDs 
Results of all models and datasets are shown in Figures 9 and 10. All of these CrIs span zero. 
Of course, it is recognised that this is not the full evidence base for Hepatitis C. Including all 
AD studies could lead to smaller CrIs, but this is outside the scope of this paper. Figure 9 shows 
the treatment effects. Although there are some noticeable differences in point estimates for the 
efficacy of PrOD RBV and SOF/LDV RBV versus TEL/PR, in each of the 24 model and 
dataset options, the ranking of the treatment regimens, in terms of attainment of SVR, is 
unchanged. SOF/LDV RBV is ranked highest, followed by PrOD  RBV, TEL/PR and 
finally BOC/PR. This is consistent with Gray et al
25
, which uses all available AD evidence, 
which also found SOF/LDV RBV to be the best treatment, followed by PrOD RBV. Figure 
10 shows the covariate effects. The difference in the length of the CrIs between identical and 
exchangeable covariate interactions again highlights the need to check model choice if we wish 
to draw conclusions on the effect of the covariate.There is considerably more discrepancy 
between models for the covariate effects, with the identical models in particular being closer to 
the line of no effect. Depending on the model and dataset there are estimates on either side of 
this line.  
 
The size of the credible intervals is solely dependent on the posterior SDs which is 
detailed in Tables 5 and 6. For all three model assumptions the posterior SD of each covariate 
effect decreases when including IPD. As we have identified that the identical model would not 
be appropriate for this network, the identical model may produce overly precise SDs, as shown 
in the coverage probability of the simulation study in Figure 5. The posterior SD of the 
treatment effects are sometimes increased and sometimes decreased. In cases where including 
extra IPD increases posterior SD of the estimated treatment effect, this may indicate between 
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study heterogeneity. It should be noted that the main decrease in posterior SD of the treatment 
effect is for the identical model, which is most likely not the correct model for this network.  
 
Tables 7 and 8 show the effect of IPD and model choice on the posterior SD for each 
combination of IPD and AD. Cells are colour coded based on the size of the posterior SD 
within each model (row). In Table 7 we see that including IPD from any one study decreases 
the posterior SD of the covariate effects for identical and exchangeable. For the independent 
assumption, some of the posterior SDs are not decreased with IPD from only Wehmeyer or 
TRIO, as neither one of these has studied all four treatments. We again see some evidence of 
disagreement between studies as some posterior SDs are increased when IPD are included from 
more than one study. Overall, however, the full IPD dataset has posterior SDs that are quite 
close to the smallest posterior SD, which indicates that there is not considerable disagreement. 
Once again we see that the exchangeable model produces the highest posterior SDs, especially 
for covariate effects. In Table 8 we see that the use of IPD does not make as much difference to 
the posterior SD of the treatment effect. As highlighted in the simulation study, this may 
indicate heterogeneity between studies and therefore we should use the full IPD where possible 
so as not to rely on overly precise posterior SDs.  
 
4. Discussion 
Through our simulation study we found a variety of benefits of using IPD, even when IPD are 
not available for all studies. Therefore, when conducting an NMA one should not abandon an 
IPD approach, even if IPD are unavailable for some studies. The proportion of IPD that is 
available, in combination with any available AD, could have great benefits to an NMA. It 
decreases MAEs of estimates and posterior SDs in the majority of cases. It also increases our 
ability to choose between model assumptions through the DIC. This is almost impossible using 
just AD. When the model is misspecified, IPD may cause overconfidence in posterior SD 
leading to poor coverage probabilities. However, using IPD to choose between models should 
limit the frequency with which an incorrect model is used. Therefore we recommend using IPD 
when and where possible.  
Tables 9 and 10 summarise the findings of the simulation study for both model 
comparisons and the use of IPD, in order to identify situations when model choice is 
particularly important and when IPD are mostuseful. Ideally we wish to have the coverage 
probability of the CrI as close as possible to the target probability (in this case 95 ), while 




 have highlighted that identical models are often used in practice and for this 
reason their paper explored the properties of only the identical model in greater depth. 
However, as we have seen from the simulationstudy, assuming identical interaction effects 
when they are not identical can be quite problematic due to the overly precise estimates. On the 
other hand, in the simulation study, through examining the DIC, the identical model is very 
rarely incorrectly identified as the best model, so if this model has the lowest DIC it is quite 
likely to be correct.  
 
If a model has been identified as non-identical it appears that an independent model 
may be preferable over an exchangeable model, due to the unnecessarily high SDs from the 
exchangeable model. However, as the independent model can produce quite low coverage of 
the covariate effect, it is worth investigating whether an identical model is more appropriate. 
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Additionally, we have only considered cases with five treatments in the simulation study and 
four treatments in the Hepatitis C network. Perhaps if there were many more treatments, an 
exchangeable model may be more appropriate than independent. Similarly, we have only 
examined the scenario when all the treatments are either identical or non identical. There are 
possibly many cases where there are a few different classes of treatments. Therefore these 
could possibly be modelled as a joint distribution with independence or exchangeablity 
between groups of treatments and exchangeable or identical interactions within groups. 
Furthermore we could possibly examine more informative priors for the hyper-parameters on 
the exchangeable interaction to increase precision.  
 
In the Hepatitis C infection example the ranking of treatments remained the same 
regardless of the amount of IPD included. This is consistent with the conclusion of Tudur 
Smith et al
13
, that in many cases similar conclusions can be drawn from both AD and IPD 
NMA. However, the use of IPD also allowed us to conclude that we should use a model which 
assumes non-identical interactions between the treatments and the covariates. The use of IPD 
also reduced the posterior SDs for the covariate effects, and occasionally reduced posterior 
SDs for the treatment effects, which may indicate some heterogeneity between studies. By 
including the IPD we can gain more information about covariates, (although it is worth 
pointing out that the covariates are centered in our models, and therefore interpretation of the 
results should be done with this in mind). Increased information on the covariates either 
produce more precise estimates of effect, or allow us to identify between study heterogeneity. 
Of course, part of the motivation for meta analysis is that no one study can provide complete 
information about treatments. Therefore, identifying and including heterogeneous studies is 
crucial as it provides a more accurate picture of the effect of treatments on a wider scale.  
 
Overall, we would recommend using IPD when available, particularly due to the added 
benefit of choosing the correct model. In the case where no IPD are available, we would 
recommend trying to obtain IPD from at least one or two datasets to ensure that the model is 
specified correctly. This could also lead to more accurate and precise estimates. While any 
extra IPD study is valuable, the marginal benefits decrease as more IPD are included in the 
NMA. In practice all studies should be included when undertaking an NMA, including those 
with just AD.  
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6. Highlights 
It is generally accepted that including Individual Patient Data (IPD) in a Network Meta 
Analysis (NMA) is the gold standard of systematic review. However, few studies have been 
carried out to quantify the benefit of an IPD NMA over an aggregate data (AD) NMA. In this 
work, we use a simulation study to quantify the benefits of using IPD. We find that a 
particularly beneficial use of IPD is to assess the way in which the effect of a treatment is 
affected by certain patient covariates (i.e. treatment by covariate interaction). This can have an 
impact when deciding how to incorporate patient covariates into an NMA. We also present the 
consequences of making an incorrect assumption about this interaction. Overall we 
recommend that one should use IPD where possible, which may mean using IPD for some 
studies and AD for other studies.  
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